Insider · CIK 0001968554
Julie Jordan
Files at NGNE (Neurogene Inc.). First filing Mar 30, 2026, latest Mar 30, 2026.
Julie Jordan files SEC Form 4 as officer at NGNE (Neurogene Inc.). Since Mar 30, 2026, Julie Jordan has reported 0 open-market buys worth $0 and 1 open-market sell worth $18k, the latest filed on Mar 30, 2026.
A track record needs three past buys with six months of prices behind them; Julie Jordan has 0, so none is measured yet.
The newest scored trade: sold $18k of NGNE on Mar 26, 2026, filed Mar 30, 2026, scored 10 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $18k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NGNE: Neurogene Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | Neurogene Inc. | $18k 828 shares | -6% | +192% from low-38% from high |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | NGNE Neurogene Inc. | SOpen-market sale Common Stock10b5-1 | -828 | $21.89 | $18k | 12,472 | Mar 30, 2026 |
| Feb 20, 2026 | NGNE Neurogene Inc. | AGrant or award Common Stock | +4,900 | $0.00 | $0 | 13,300 | Feb 24, 2026 |
| Feb 20, 2026 | NGNE Neurogene Inc. | AGrant or award Stock Option (Right to Buy)derivative | +29,600 | $0.00 | $0 | 29,600 | Feb 24, 2026 |
| Mar 26, 2025 | NGNE Neurogene Inc. | AGrant or award Common Stock | +8,400 | $0.00 | $0 | 8,400 | Mar 28, 2025 |
| Mar 26, 2025 | NGNE Neurogene Inc. | AGrant or award Employee Stock Option (Right to buy)derivative | +50,300 | $0.00 | $0 | 50,300 | Mar 28, 2025 |
Questions about Julie Jordan
Answered from the filings on this page, as of the latest one.
Is Julie Jordan buying or selling?
In the last 12 months Julie Jordan reported 0 open-market buys worth $0 and 1 open-market sell worth $18k on SEC Form 4; the latest was sold $18k of NGNE on Mar 26, 2026. Grants, option exercises and tax withholding are not counted.
How did Julie Jordan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Julie Jordan has 0.
Where does Julie Jordan file Form 4?
Julie Jordan has filed Form 4 at NGNE (Neurogene Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.